Literature DB >> 6124000

Rapid thymomas induced by Abelson murine leukemia virus.

W D Cook.   

Abstract

Abelson murine leukemia virus (A-MuLV) is derived from the thymotropic Moloney leukemia virus. However, injection of mice with A-MuLV by conventional routes results in rapidly arising peripheral and bone marrow lymphomas, not thymomas or T cell tumors. In this study thymomas have been induced by intrathymic injection of A-MuLV into BALB/c and C57BL/Ka mice. In both strains thymomas arose with short latent periods, comparable with the latencies of nonthymic tumors induced by intraperitoneal injection of A-MuLV and significantly shorter than those of thymomas induced by intrathymic injection of Moloney leukemia virus. Cells of the BALB/c thymomas were predominantly Thy-1-; those of C57BL/Ka thymomas were predominantly Thy-1+. Tissue culture lines were established and cloned. Some of these expressed low amounts of Thy-1 and one also expressed Lyt-1. Virus from cloned lines transformed 3T3 cells in vitro and induced Abelson disease in vivo when injected intraperitoneally into neonates. The A-MuLV p120 protein has been precipitated from metabolically labeled cell lysates of one cloned Thy-1+ line. These results show that A-MuLV can transform cells in the T lymphocyte lineage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124000      PMCID: PMC346319          DOI: 10.1073/pnas.79.9.2917

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Direct transformation of 3T3 cells by Abelson murine leukaemia virus.

Authors:  C D Scher; R Siegler
Journal:  Nature       Date:  1975-02-27       Impact factor: 49.962

2.  Clonal cells lines from a feral mouse embryo which lack host-range restrictions for murine leukemia viruses.

Authors:  J W Hartley; W P Rowe
Journal:  Virology       Date:  1975-05       Impact factor: 3.616

3.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

4.  The separation of different cell classes from lymphoid organs. IX. A simple and rapid method for removal of damaged cells from lymphoid cell suspensions.

Authors:  H von Boehmer; K Shortman
Journal:  J Immunol Methods       Date:  1973-04       Impact factor: 2.303

5.  Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice.

Authors:  M Potter; M D Sklar; W P Rowe
Journal:  Science       Date:  1973-11-09       Impact factor: 47.728

6.  Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

9.  Cloning of mouse myeloma cells and detection of rare variants.

Authors:  P Coffino; R Baumal; R Laskov; M D Scharff
Journal:  J Cell Physiol       Date:  1972-06       Impact factor: 6.384

10.  A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  30 in total

1.  Chronic myeloproliferative disease induced by site-specific integration of Abelson murine leukemia virus-infected hemopoietic stem cells.

Authors:  X D Han; P M Wong; S W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 2.  Abelson virus as a probe for prothymocytes.

Authors:  W D Cook
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

3.  Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase.

Authors:  S P Yee; D Mock; P Greer; V Maltby; J Rossant; A Bernstein; T Pawson
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

4.  Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets.

Authors:  G F Tidmarsh; S Heimfeld; C A Whitlock; I L Weissman; C E Müller-Sieburg
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

5.  A bcr-v-abl oncogene induces lymphomas in transgenic mice.

Authors:  I K Hariharan; A W Harris; M Crawford; H Abud; E Webb; S Cory; J M Adams
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

6.  Early pre-B-cell transformation induced by the v-fms oncogene in long-term mouse bone marrow cultures.

Authors:  G V Borzillo; C J Sherr
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  Transcriptionally active DNA region that rearranges frequently in murine lymphoid tumors.

Authors:  J M Adams; S Gerondakis; E Webb; J Mitchell; O Bernard; S Cory
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.

Authors:  S S Clark; E Chen; M Fizzotti; O N Witte; V Malkovska
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  v-Abl activates c-myc transcription through the E2F site.

Authors:  K K Wong; X Zou; K T Merrell; A J Patel; K B Marcu; S Chellappan; K Calame
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  Retrovirus-induced spongiform encephalopathy: the 3'-end long terminal repeat-containing viral sequences influence the incidence of the disease and the specificity of the neurological syndrome.

Authors:  L DesGroseillers; E Rassart; Y Robitaille; P Jolicoeur
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.